stockrowHarmony Biosciences Holdings, Inc.
HRMY Healthcare Biotechnology
Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024.
- Revenue
- +12.3%
- EPS
- −6.24%
- Free cash flow
- −29.4%
- Total debt
- −11.5%
Quarter to September 2026, against a year earlier
Follow HRMY
Alert me
Harmony Biosciences Holdings, Inc. (HRMY) EBITDA
Harmony Biosciences Holdings, Inc.'s EBITDA for fiscal 2025 was $232.9M, up 9.16% from $213.4M in fiscal 2024. Over the twelve months to 30 September 2026 it was $243.7M. Over the past ten years it has ranged from −$142.1M (fiscal 2019) to $232.9M (fiscal 2025) — the current reading is the highest in ten years. Harmony Biosciences Holdings, Inc. ranks 18th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $232.9M | 9.16% |
| FY2024 | $213.4M | (1.19%) |
| FY2023 | $215.9M | 49.13% |
| FY2022 | $144.8M | 33.33% |
| FY2021 | $108.6M | 266.48% |
| FY2020 | $29.6M | — |
| FY2019 | −$142.1M | — |
| FY2018 | −$41.3M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $59.6M | (37.28%) |
| Jun 2026 | $95.0M | 119.99% |
| Mar 2026 | $43.2M | (5.83%) |
| Dec 2025 | $45.9M | (35.66%) |
| 25 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| HRMY Harmony Biosciences Holdings, Inc. | $243.7M |
| FTRE Fortrea Holdings Inc. compare | $91.5M |
| MESO Mesoblast Limited compare | −$57.9M |
| TRVI Trevi Therapeutics, Inc. compare | −$59.4M |
| SRPT Sarepta Therapeutics, Inc. compare | −$101.5M |
| MAZE Maze Therapeutics, Inc. compare | −$143.2M |
| TRAX First Tracks Biotherapeutics, Inc. compare | −$164.7M |
| VIR Vir Biotechnology, Inc. compare | −$198.6M |
| REPL Replimune Group, Inc. compare | −$266.7M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item